Letters to the Editor

Letters to the Editor

A Thought-Provoking Question

In our September issue, Elisabeth M. Battinelli, MD, PhD, responded to a colleague seeking advice on managing a patient who developed deep-vein thrombosis (DVT)...

Can’t We All Get Along?

In his August 2017 editorial (“Musing on Medical Marvels”), Keith Stewart, MBChB, MBA, recounted the amazing innovations in cancer treatment in the past 20...

CROs and Cons

In his June 2017 Editor’s Corner (“Contract Research Agonizations”), ASH Clinical News’ Editor-in-Chief Mikkael Sekeres, MD, MS, called for an end to the bureaucratic...

Advocating for a Return to Common Sense in Clinical Research

In his June 2017 Editor’s  Corner (“Contract Research Agonizations”), ASH Clinical News’ Editor-in-Chief Mikkael Sekeres, MD, MS, called for an end to the bureaucratic...

Impatient Practicum

In his April 2017 Editor’s Corner, Editor-in-Chief Mikkael Sekeres issued his annual missive to the American Board of Internal Medicine (“Letter from a Cleveland...

Not-So-NICE One

In December 2016, we published an Online Exclusive item reporting on the United Kingdom’s National Institute for Health and Care Excellence’s (NICE) review of...

Another Clinical Research Secret

In the December 2016 Editor’s Corner (“So You Say You Want to Be a Clinical Researcher?”), Mikkael A. Sekeres, MD, MS, offered advice for...

The Family That Puzzles Together …

In December’s issue, Associate Editor David Steensma, MD, shared his lifelong love of word games, and how he went from fighting over the newspaper...

Marrow-Minded

In November’s Editor’s Corner, David Steensma, MD, recounted the “absurdly exotic experience” of eating bone marrow in a café in Milan after speaking about...

A Response on Email Etiquette

In October’s Editor’s Corner, Editor-in-Chief Mikkael A. Sekeres, MD, MS, and his colleague at Cleveland Clinic, Jennifer Lonzer, MA, provided “A Primer on Email...
Advertisement

Current Issue

November 2017, Volume 3, Issue 13

This issue features a behind-the-scenes look at the ASH annual meeting, bringing newly approved gene therapies to patients, and more.